Effect of extracellular ATP on cisplatin-induced cytotoxicity in human ovarian carcinoma cells

Chemotherapy

Volumn 56, Issue 1, 2010, Pages 1-8

  Rotte, Anand ^a   Garmann, Dirk ^a   Buß, Irina ^a   Jaehde, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

ATP; Cancer; Cisplatin; Cytotoxicity

Indexed keywords

ADENOSINE TRIPHOSPHATE; CISPLATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG SENSITIZATION; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICROSCOPY, ATOMIC FORCE; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 77950528508     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000287351     Document Type: Article

References (41)

1. Markman M: Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. Trends Pharmacol Sci 2008; 29: 515-519.
2. Hussain SA, Ma YT, Cullen MH: Management of metastatic germ cell tumors. Expert Rev Anticancer Ther 2008; 8: 771-784.
3. Öksüzoglu B, Abali H, Hayran M, Yildirim N, Budakoglu B, Zengin N: Capecitabine and cisplatin combination is an active and welltolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes. Chemotherapy 2008; 54: 352-356.
4. Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007; 63: 12-31.
5. Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307-320.
6. Altaha R, Liang X, Yu JJ, Reed E: Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004; 14: 959-970.
7. Goto S, Yoshida K, Morikawa T, Urata Y, Suzuki K, Konda T: Augmentation of transport for cisplatin-glutathione adduct in cisplatinresistant cancer cells. Cancer Res 1995; 55: 4297-4301.
8. Ishikawa T, Ali-Osman F: Glutathione-associated cis - diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 1993; 268: 20116-20125.
9. Gately DP, Howell SB: Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993; 67: 1171-1176.
10. Zisowsky J, Koegel S, Leyers S, Devarakonda K, Kassack MU, Osmak M, Jaehde U: Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 2007; 73: 298-307.
11. Zisowsky J, Becker A, Weykam S, Kassack M, Jaehde U: Assessment of platinum sensitivity in human tumor cells. Int J Clin Pharmacol Ther 2003; 41: 612-613.
12. Lin X, Okuda T, Holzer A, Howell SB: The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 2002; 62: 1154-1159.
13. Ishida S, Lee J, Thiele DJ, Herskowitz I: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002; 99: 14298-14302.
14. Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T: The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 2007; 26: 71-83.
15. Binks SP, Dobrota M: Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine. Biochem Pharmacol 1990; 40: 1329-1336.
16. Centerwall CR, Tacka KA, Kerwood DJ, Goodisman J, Toms BB, Dubowy RL, Dabrowiak JC: Modification and uptake of a cisplatin carbonato complex by Jurkat cells. Mol Pharmacol 2006; 70: 348-355.
17. Deli T, Csernoch L: Extracellular ATP and cancer - an overview with special reference to P2 purinergic receptors. Pathol Oncol Res 2008; 14: 219-231.
18. White N, Burnstock G: P2 receptors and cancer. Trends Pharmacol Sci 2006; 27: 211-217.
19. Estrela JM, Obrador E, Navarro J, Lasso de la Vega MC, Pellicer JA: Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays. Nat Med 1995; 1: 84-88.
20. Lasso de la Vega MC, Terradez P, Obrador E, Navarro J, Pellicer JA, Estrela JM: inhibition of cancer growth and selective glutathione depletion in Ehrlich tumour cells in vivo by extracellular ATP. Biochem J 1994; 298: 99-105.
21. Palomares T, Bilbao P, del Olmo M, Castro B, Calle Y, Alonso-Varona A: In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoxime on chemosensitization and tumor growth of B16 melanoma. Melanoma Res 1999; 9: 233-242.
22. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR: Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of doxorubicin. Chemotherapy 2007; 53: 210-217.
23. Kitagawa T, Akamatsu Y: Modulation of passive permeability by external ATP and cytoskeleton- attacking agents in cultured mammalian cells. Biochim Biophys Acta 1983; 734: 25-32.
24. Mure T, Sano K, Kitagawa T: Modulation of membrane permeability, cell proliferation and cytotoxicity of antitumor agents by external ATP in mouse tumor cells. Jpn J Cancer Res 1992; 83: 121-126.
25. Maymom R, Bar-Shira MB, Cohen-Armon A, Leibovici J: Enhancing effect of ATP on intracellular Adriamycin penetration in human ovarian cancer cell lines. Biochim Biophys Acta 1994; 1201: 173-178.
26. Hatta Y, Takahashi M, Enomoto Y, Takahashi N, Sawada U, Horie T: Adenosine triphosphate (ATP) enhances the antitumor effect of etoposide (VP16) in lung cancer cells. Oncol Rep 2004; 12: 1139-1142.
27. Hatta Y, Itoh T, Baba M, Miyajima T, Shimojima H, Sawada U, Horie T: Purging in autologous hemaptopoietic stem cell transplantation using adenosine triphosphate (ATP) and 4-hydroperoxycyclophosphamide (4-HC). Leuk Res 2002; 25: 477-482.
28. Maruyama K, Ohta T, Ito S: Involvement of mitochondrial Na + -Ca 2+ exchange in intracellular Ca 2+ increase induced by ATP in PC12 cells. Brain Res 2004; 1013: 40-50.
29. Tanaka N, Kawasaki K, Nejime N, Kubota Y, Nakamura K, Kunitomo M, Takahashi K, Hashimoto M, Shinozuka K: P2Y receptormediated Ca 2+ signaling increases human vascular endothelial cell permeability. J Pharmacol Sci 2004; 95: 174-180.
30. Bidet M, De Renzis G, Martial S, Rubera I, Tauc M, Poujeol P: Extracellular ATP increases [Ca 2+ ] i in distal tubule cells. I. Evidence for a P2Y2 purinoceptor. Am J Physiol Renal Physiol 2000; 279:F92-F101.
31. Conigrave AD, Weyden L, Holt L, Jiang L, Wilson P, Christopherson RI, Morris MB: Extracellular ATP-dependent suppression of proliferation and induction of differentiation of human HL-60 leukemia cells by distinct mechanisms. Biochem Pharmacol 2000; 60: 1585-1591.
32. Weisman GA, Lustig KD, Lane E, Huang N, Belzer I, Friedberg I: Growth inhibition of transformed mouse fibroblasts by adenine nucleotides occurs via generation of extracellular adenosine. J Biol Chem 1988; 263: 12367-12372.
33. Schneider C, Wiendl H, Ogilvie A: Biphasic cytotoxic mechanism of extracellular ATP on U-937 human histiocytic leukemia cells: involvement of adenosine generation. Biochim Biophys Acta 2001; 1538: 190-205.
34. Seetulsingh-Goorah SP, Stewart BW: Growth inhibition of HL-60 cells by extracellular ATP: concentration-dependent involvement of a P 2 receptor and adenosine generation. Biochem Biophys Res Commun 1998; 250: 390-396.
35. Beijer S, Gielisse EAR, Hupperets PS, van den Borne BEM, van den Beuken-van Everdingen M, Nijziel MR, van Henten AMJ, Dagnelie PC: Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients. Invest New Drugs 2007; 25: 571-579.
36. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF: Characterization of a cis -diamminedichloro- platinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987; 47: 414-418.
37. Shabbir M, Ryten M, Thompson C, Mikhailidis D, Burnstock G: Characterization of calcium-independent purinergic receptormediated apoptosis in hormone-refractory prostate cancer. BJU Int 2007; 101: 352-359.
38. Safaei R, Katano K, Larson BJ, Samimi G, Holzer AK, Naerdemann W, Tomioka M, Goodman M, Howell SB: Intracellular localization and trafficking of fluorescein-labelled cisplatin in human ovarian carcinoma cells. Clin Cancer Res 2005; 11: 756-767. (Pubitemid 40116905)
39. Safaei R, Howell SB: Copper transporters regulate the cellular pharmacology and sensitivity of Pt drugs. Crit Rev Oncol Hematol 2005; 53: 13-23.
40. Kalayda GV, Wagner CH, Buss I, Reedijk J, Jaehde U: Altered localization of copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer 2008; 8: 175.
41. Kitagawa T, Akamatsu Y: Control of passive permeability of Chinese hamster ovary cells by extracellular and intracellular ATP. Biochim Biophys Acta 1981; 649: 76-82.